Neurometrix (NASDAQ: NURO) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its rivals? We will compare Neurometrix to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.

Earnings and Valuation

This table compares Neurometrix and its rivals revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Neurometrix $15.72 million -$13.27 million -0.10
Neurometrix Competitors $827.23 million $159.49 million 34.82

Neurometrix’s rivals have higher revenue and earnings than Neurometrix. Neurometrix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Neurometrix and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurometrix 0 0 2 0 3.00
Neurometrix Competitors 324 1485 2600 105 2.55

Neurometrix presently has a consensus target price of $26.00, suggesting a potential upside of 1,190.32%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.26%. Given Neurometrix’s stronger consensus rating and higher probable upside, research analysts plainly believe Neurometrix is more favorable than its rivals.

Volatility and Risk

Neurometrix has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Neurometrix’s rivals have a beta of 1.08, suggesting that their average share price is 8% more volatile than the S&P 500.

Insider & Institutional Ownership

6.5% of Neurometrix shares are owned by institutional investors. Comparatively, 63.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 4.4% of Neurometrix shares are owned by company insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Neurometrix and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurometrix -75.12% -207.39% -133.39%
Neurometrix Competitors -128.47% -37.35% -10.52%


Neurometrix rivals beat Neurometrix on 8 of the 12 factors compared.

About Neurometrix

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Receive News & Ratings for Neurometrix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix Inc and related companies with's FREE daily email newsletter.